Introduction: To assess the neutralization breadth of
RBD-NP-elicited Abs, we evaluated serum neutralizing activity against a panel of pseudotyped viruses comprising wild-type (
D614G) SARS-CoV-2
S and nine single-residue SARS-CoV-2
RBD mutants detected in clinical isolates (
G446S,
Y453F,
L455F,
T478I,
E484A/K,
F486L,
S494P, and
N501Y) as well as the B.1.1.7 (H69-V70 deletion, Y144 deletion,
N501Y,
A570D,
P681H,
T716I,
PMID: 33758892
2021
medRxiv